Scientific article
French

Cannabinoïdes médicaux dans les douleurs chroniques : aspects pharmacologiques

Published in

Revue médicale suisse, vol. 11, no. 480, p. 1390,1392-1394

Publication date

2015

Abstract

In Switzerland, medical cannabinoids can be prescribed under compassionate use after special authorization in justified indications such as refractory pain. Evidence of efficacy in pain is limited and the clinical benefit seems to be modest. Their drug-drug interactions (DDI) profile is poorly documented. Cytochromes P450 (CYP) 2C9 and 3A4 are involved in the metabolism of tetrahydrocannabinol and cannabidiol, which implies possible DDI with CYP450 inhibitor and inducer, such as anticonvulsivants and HIV protease inhibitors, which may be prescribed in patients with neuropathic pain.

Keywords

  • Cannabinoids/pharmacology/therapeutic use
  • Chronic Pain/drug therapy
  • Drug Interactions
  • Humans
  • Medical Marijuana/pharmacology/therapeutic use
  • Switzerland
  • Treatment Outcome

Citation (ISO format)

ING LORENZINI, Kuntheavy et al. Cannabinoïdes médicaux dans les douleurs chroniques : aspects pharmacologiques. In: Revue médicale suisse, 2015, vol. 11, n° 480, p. 1390,1392–1394.

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

1660-9379
707views
5downloads

Technical informations

Creation

11/12/2015 15:34:00

First validation

11/12/2015 15:34:00

Update

14/03/2023 23:59:08

Status update

14/03/2023 23:59:08

Last indexation

31/10/2024 02:19:07
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated